Blackstone unit to invest $350m in pharma company

Blackstone Life Sciences announced that it will lead a $350 million royalty and equity investment in Reata Pharmaceuticals as it works on a potential therapy for a rare Alport . . .

Continue Reading With a Free Trial

Unlock this article instantly, along with the rest of our premium content, newsletters and mandate charts.

Already a subscriber? Log in.

Related Articles

Back to top button

Get our daily news digest
in your inbox

Our FREE mailing list brings you daily alts intel.

Thank you for subscribing.

Something went wrong.